Mesenchymal Stromal Cells as Rescue Therapy for Refractory Chronic Lung Allograft Dysfunction: Analysis of Immunoregulatory Effects In Vitro and Preliminary Data of Safety In Vivo
Purpose: Mesenchymal stromal cells (MSCs) have been reported as a promising therapy for CLAD due to their immunomodulatory and tolerogenic properties. To assess MSC immunoregulatory/anti-remodeling effects in vitro and the safety profile in vivo we: 1) assessed bone marrow-derived MSC (BMSC) activity on normal precision cut lung slices (PCLS) cultures and 2) we monthly administered 1 x 106 BMSC/Kg BW to end stage CLAD patients who had previously failed several treatment lines including azithromycin, ECP and montelukast.
Source: The Journal of Heart and Lung Transplantation - Category: Transplant Surgery Authors: , S. Bozzini, E. Bozza, C. Bagnera, D. Briganti, K. Mucaj, G. Melloni, P. Comoli, F. Meloni Source Type: research
More News: Azithromycin | Bone Graft | Cardiology | Heart | Heart Transplant | Lung Transplant | Transplant Surgery | Transplants | Zithromax